Ajit Raisinghani is a Cardiology physician. OpenAlex indexes 81 publications with 4,156 citations (h-index 25).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 W Arbor Dr
San Diego, CA 921038411
Telephone
800-926-8273Registry record last updated 9 Jul 2019.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Edwards Lifesciences CorporationProgram year20252 payments
- Kiniksa Pharmaceuticals International, plcProgram year202440 payments$26,560openpaymentsdata.cms.gov ↗
- Abbott LaboratoriesProgram year202411 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
85.6%Statin26.3%Rosuvastatin Calcium52%Atorvastatin Calcium38%Pravastatin Sodium8%Simvastatin1%Part D<11 patientsBeta blocker15.3%Metoprolol Succinate52%Carvedilol23%Sotalol8%Bisoprolol Fumarate7%Metoprolol Tartrate6%Labetalol Hcl3%Part D<11 patients+ 13 more classes in this area
Blood & clotting
10.4%Factor Xa inhibitor9.4%Eliquis91%Xarelto9%Part D≥86 patientsP2Y12 inhibitor1%Clopidogrel100%Part D≥16 patientsMetabolism & gastrointestinal
3.7%SGLT2 inhibitor3.1%Jardiance72%Farxiga28%Part D<11 patientsPotassium supplement0.6%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
European Heart Journal - Cardiovascular Pharmacotherapy
2024 - RILONACEPT UTILIZATION IN A STEROID-SPARING PARADIGM FOR RECURRENT PERICARDITIS: REAL WORLD EVIDENCE DEMONSTRATING INCREASED ADOPTION
Journal of the American College of Cardiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”